Articles tagged "HLA antibodies"

2018 American Transplant Congress
Change in Estimated Glomerular Filtration Rate Pre and Post Development of Donor-Specific Antibodies after Kidney Transplantation
B. Ho,¹ S. Montag,^1,2 H. Bhagat,³ K. Atiemo,¹ A. Daud,¹ R. Kang,¹ L. Zhao,^1,2 J. Schwartz,³ D. Ladner.¹
¹Northwestern University Transplant and Outcomes Research Collaborative (NUTORC), Chicago; ²Dept of Preventive Medicine, Northwestern University, Chicago; ³Astellas Pharma Global Development, Inc., Northbrook.
Formation of de novo donor-specific antibodies (dnDSA) against human leukocyte antigens contributes to inferior kidney transplant (KT) outcomes. We assessed the effect of dnDSA on…
2018 American Transplant Congress
Donor-Derived Cell-Free DNA Identifies Antibody-Mediated Rejection with Graft Injury in DSA-Positive Kidney Transplant Recipients
S. Jordan,¹ S. Bunnapradist,² J. Bromberg,³ A. Langone,⁴ D. Hiller,⁵ J. Yee,⁵ J. Sninsky,⁵ R. Woodward,⁵ A. Matas.⁶
¹Cedars-Sinai Medical Center, Los Angeles, CA; ²UCLA, Los Angeles, CA; ³University of Maryland School of Medicine, Baltimore, MD; ⁴Vanerbilt University Medical Center, Nashville, TN; ⁵CareDx, Brisbane, CA; ⁶University of Minnesota School of Medicine, Minneapolis, MN.
Purpose: Donor-derived cell-free DNA (dd-cfDNA) discriminates active rejection in kidney transplant patients. Donor-specific antibodies (DSA) to HLA antigens are associated with risk of antibody-mediated rejection…
2018 American Transplant Congress
Not All HLA Mismatches Are Equal: Determining the Relative De Novo DSA Induction Capacity of HLA Mismatches
V. Jucaud,¹ L. Rebellato,² K. Briley,² A. Maldonado,³ C. Haisch,² P. Bolin,² S. Kendrick,⁴ H. Jones,⁴ K. McLawhorn,⁴ D. Leeser,² M. Everly.¹
¹Terasaki Research Institute, Los Angeles, CA; ²East Carolina University, Greenville, NC; ³Vidant Medical Center, Greenville, NC; ⁴Eastern Nephrology Associates, Greenville, NC.
We studied the immunogenicity, defined as the development of de novo DSA (dnDSA), of HLA-A, -B, -DR and -DQ MM (serological) in a cohort of…
2018 American Transplant Congress
Can We Expect the “Unexpected”?
D. Pinelli, A. Tambur.
Northwestern University, Chicago.
A known, seemingly paradoxical, phenomenon of the HLA system is the high overall degree of homology among different HLA alleles, despite vast polymorphism in the…
2018 American Transplant Congress
A Calculated Panel Reactive Antibody (CPRA) Calculator Supporting Both Allele-Level and Antigen-Level HLA Specificities
L. Gragert,^1,2 E. Kransdorf,³ N. Kaur,¹ M. Maiers,² J. Kobashigawa,³ M. Pando.⁴
¹Tulane University School of Medicine, New Orleans; ²National Marrow Donor Program / Be The Match, Minneapolis; ³Cedars-Sinai Heart Institute, Los Angeles; ⁴Baylor Scott and White, Temple.
Introduction:The number of HLA alleles represented on Luminex assays has increased over time, allowing for improved characterization of anti-HLA antibody specificity. Calculated Panel Reactive Antibody…
2018 American Transplant Congress
The Value of Serum Dilution on DSA Outcome Analysis in Renal Transplantation
W. Huang,¹ L. Rebellato,² K. Briley,² P. Bolin,² S. Kendrick,³ A. Maldonado,⁴ D. Leeser,² C. Haisch,² M. Everly.¹
¹Terasaki Research Institute, Los Angeles, CA; ²East Carolina University, Greenville, NC; ³Eastern Nephrology Associates, Greenville, NC; ⁴Vidant Medical Center, Greenville, NC.
Background: Recently, transplant centers have discussed the potential value of sera dilutions in assessment of donor specific anti-HLA antibodies (DSA). However, to date, no data…
2018 American Transplant Congress
Epitope/Eplet Mismatch in Pediatric Renal Transplantation and Development of Donor Specific Antibody
R. George,¹ H. Sullivan,² R. Garro,¹ P. Winterberg,¹ B. Warshaw,¹ H. Gebel,² R. Bray.²
¹Pediatric Nephrology, Emory University & Children's Healthcare of Atlanta, Atlanta, GA; ²Dept. of Pathology, Emory Transplant Center, Emory University, Atlanta, GA.
Background: De-novo donor specific antibody (DSA) is one of the strongest independent predictors of graft loss with HLA mismatching being a major risk factor for…
2018 American Transplant Congress
Increasing the Donor Pool for Highly Sensitized Patients with Allele Specific Antibodies: Optimizing the Virtual Crossmatch (vXM)
A. Zhang,¹ Z. Zaky,² J. Africa,³ D. Good,¹ R. Bray,⁴ H. Gebel.⁴
¹Allogen Laboratories, Cleveland Clinic, Cleveland; ²Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland; ³Transplant Surgery, Charleston Area Medical Center, Charleston; ⁴Pathology & Laboratory Medicine, Emory University, Atlanta.
Background:Since implementation of the current Kidney Allocation System, highly sensitized patients with 98-100% cPRA (HSPs) are receiving ~10% of deceased donor kidneys compared to <2%…
2018 American Transplant Congress
Biopsy Correlates of DSA in Antibody-Mediated Rejection: C4d vs Microvascular Inflammation Scores
C. Harris, L. Anderson, R. Khaim, J. Choudhuri, R. Shapiro, S. Florman, F. Salem, M. Menon.
Icahn School of Medicine at Mount Sinai, New York, NY.
Background: The diagnosis of antibody-mediated rejection (AMR) requires the presence of both the histologic features of AMR as well as donor-specific antibodies (DSA). Whether anti-HLA…
2018 American Transplant Congress
Generation of Calculated Panel-Reactive Antibody Values Using a Reference Panel of Bone Marrow Donors
E. Kransdorf,¹ L. Gragert,^2,4 M. Pando,³ N. Kaur,² J. Patel,¹ I. Kim,¹ X. Zhang,¹ M. Maiers,⁴ J. Kobashigawa.¹
¹Cedars-Sinai Medical Center, Los Angeles, CA; ²Tulane University School of Medicine, New Orleans, LA; ³Baylor Scott & White, Temple, TX; ⁴National Marrow Donor Program, Minneapolis, MN.
Introduction: Calculated panel-reactive antibody (CPRA) is the official metric of sensitization used by the United Network for Organ Sharing (UNOS) for kidney allocation. The reference…